Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prospective characterization of clonal hematopoiesis and its clinical associations in elderly patients.

Scientific reports·2025

Same author

An Extended Flow Cytometry Evaluation of ex Vivo Expanded NK Cells Using K562.Clone1, a Feeder Cell Line Manufactured in Brazil.

Transplantation and cellular therapy·2024

Same author

Molecular taxonomy of myelodysplastic syndromes and its clinical implications.

Blood·2024

Same author

Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.

Blood·2024

Same author

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.

NEJM evidence·2024

Same author

Molecular Characterization of a First-in-Human Clinical Response to Nimesulide in Acute Myeloid Leukemia.

Frontiers in oncology·2022

Search research articles

Related Experiment Video

Updated: May 23, 2026

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

Breakthroughs in myeloproliferative neoplasms.

Fabio P S Santos¹, Srdan Verstovsek

¹Hematology and Stem Cell Transplantation, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

Hematology (Amsterdam, Netherlands)

|April 18, 2012

Summary

Targeted therapies, including JAK2 inhibitors, are improving quality of life for Philadelphia-negative myeloproliferative neoplasms (MPNs) patients, particularly those with myelofibrosis (MF). Further research will determine if these treatments also prolong survival.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Related Experiment Videos

Last Updated: May 23, 2026

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Area of Science:

Hematology
Oncology
Molecular Biology

Background:

The JAK2V617F mutation discovery enabled targeted therapy for Philadelphia-negative myeloproliferative neoplasms (MPNs).
JAK2 inhibitors are crucial in treating myelofibrosis (MF), a type of MPN.
These inhibitors target JAK2-STAT and inflammatory cytokine signaling pathways.

Purpose of the Study:

To review the latest therapeutic advancements in Philadelphia-negative MPNs.
To highlight the role of JAK2 inhibitors in managing MF symptoms and quality of life.
To discuss other emerging treatments for MPNs.

Main Methods:

Review of current clinical trials and therapeutic strategies for MPNs.
Analysis of the mechanism of action for JAK2 inhibitors.
Evaluation of the impact of JAK2 inhibitors on MF symptoms.

Main Results:

JAK2 inhibitors significantly improve splenomegaly and constitutional symptoms in most MF patients.
Improved quality of life is a key benefit of current JAK2 inhibitor therapy.
Long-term survival benefits are under investigation.

Conclusions:

Targeted therapies, especially JAK2 inhibitors, represent a significant advancement in MPN treatment.
These therapies offer substantial symptomatic relief and improved quality of life for MF patients.
Ongoing research aims to confirm long-term survival benefits and explore novel therapeutic agents.